Zydus receives final approval and 180 days shared exclusivity from USFDA for Selexipag Tablets

Selexipag tablet is indicated in adults for the treatment of pulmonary arterial hypertension to delay disease progression and reduce the risk of hospitalization for PAH

Strides Pharma Global receives AUD 94 mn for sale of Australia's operations

The balance of AUD 94 Million was a deferred consideration backed by a secured interest-bearing instrument

CDSCO playing a significant role in providing right medicine at the right time: Dr. Mandaviya

Lynparza in combination with Abiraterone and Prednisone approved in the EU as treatment for metastatic castration-resistant prostate cancer

First PARP inhibitor and new hormonal agent combination approved for these patients in Europe

4.4 crore health records of citizens digitized and linked with ABHA

This digital linking of individual’s health records with ABHA is being carried out extensively across different health facilities of the country

Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers

Positive opinions based on significant survival benefit

Astellas, Seagen and Merck announce FDA acceptance of sBLA for PADCEV for urothelial cancer

This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting

Stake sale in GMM Pfaudler by Pfaudler

Post the sale, Patel family has become the single largest promoter shareholder in the company

Alembic receives EIR for oncology injectable formulation facility at Panelav

This was a pre-approval inspection to cover our Oncology Injectable drug products for which ANDAs were filed with USFDA

PM lays foundation stone for National Institute for One Health in Nagpur

The Institute will focus on increasing preparedness and laboratory capabilities for identification of novel and unknown zoonotic agents